Our goal is to identify and validate novel therapeutic targets for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and additional hematolgical malignancies, with a strong focus on cancer metabolism, using genetically-engineered mouse models, as well as human cell lines and patient-derived xenografts (PDXs). We use a three-pronged approach, using (i) genetically-engineered mouse models targeting different relevant targets; (ii) novel experimental drugs; and (iii) dietary interventions.
Program Faculty
- Daniel Herranz
- Associate Professor
- Department: Department of Pharmacology
- Graduate Program(s): Cellular and Molecular Pharmacology | Microbiology and Molecular Genetics
- Major Research Interest(s): Cancer Biology, Drug Discovery, Epigenetics/ Chromatin, Metabolism / Nutrition, Signaling
- Research Techniques: Cell Biology, Genetic engineering, Metabolomics, Proteomics, Transcriptomics
- Research Organism(s): Cell lines, Mice
- Rotation Faculty
- Phone: 1.7322354064
- Email:
This email address is being protected from spambots. You need JavaScript enabled to view it. - Rutgers Robert Wood Johnson Medical School
- Cancer Institute of NJ, Room 3037
- 195 Little Albany Street
- New Brunswick, NJ 08901
- Key Words: leukemia; mouse models; cancer metabolism; experimental therapeutics
- Lab Site URL